Browse FLOT2

Summary
SymbolFLOT2
Nameflotillin 2
Aliases ECS-1; ECS1; Flotillin 2 (epidermal surface antigen 1); membrane component, chromosome 17, surface marker 1 ......
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Peripheral membrane protein Membrane, caveola Peripheral membrane protein Endosome Membrane Lipid-anchor Note=Membrane-associated protein of caveolae.
Domain PF01145 SPFH domain / Band 7 family
PF15975 Flotillin
Function

May act as a scaffolding protein within caveolar membranes, functionally participating in formation of caveolae or caveolae-like vesicles. May be involved in epidermal cell adhesion and epidermal structure and function.

> Gene Ontology
 
Biological Process GO:0001765 membrane raft assembly
GO:0001767 establishment of lymphocyte polarity
GO:0001768 establishment of T cell polarity
GO:0002694 regulation of leukocyte activation
GO:0002696 positive regulation of leukocyte activation
GO:0007009 plasma membrane organization
GO:0007159 leukocyte cell-cell adhesion
GO:0007163 establishment or maintenance of cell polarity
GO:0008544 epidermis development
GO:0022407 regulation of cell-cell adhesion
GO:0022409 positive regulation of cell-cell adhesion
GO:0030010 establishment of cell polarity
GO:0031579 membrane raft organization
GO:0031647 regulation of protein stability
GO:0032878 regulation of establishment or maintenance of cell polarity
GO:0042110 T cell activation
GO:0042692 muscle cell differentiation
GO:0042982 amyloid precursor protein metabolic process
GO:0042987 amyloid precursor protein catabolic process
GO:0044091 membrane biogenesis
GO:0044860 protein localization to plasma membrane raft
GO:0045445 myoblast differentiation
GO:0045661 regulation of myoblast differentiation
GO:0045785 positive regulation of cell adhesion
GO:0050821 protein stabilization
GO:0050863 regulation of T cell activation
GO:0050865 regulation of cell activation
GO:0050867 positive regulation of cell activation
GO:0050870 positive regulation of T cell activation
GO:0051147 regulation of muscle cell differentiation
GO:0051249 regulation of lymphocyte activation
GO:0051251 positive regulation of lymphocyte activation
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0071593 lymphocyte aggregation
GO:0071709 membrane assembly
GO:0072657 protein localization to membrane
GO:0072659 protein localization to plasma membrane
GO:0090002 establishment of protein localization to plasma membrane
GO:0090150 establishment of protein localization to membrane
GO:1902991 regulation of amyloid precursor protein catabolic process
GO:1902992 negative regulation of amyloid precursor protein catabolic process
GO:1903037 regulation of leukocyte cell-cell adhesion
GO:1903039 positive regulation of leukocyte cell-cell adhesion
GO:1903044 protein localization to membrane raft
GO:1903903 regulation of establishment of T cell polarity
GO:1903905 positive regulation of establishment of T cell polarity
GO:1990778 protein localization to cell periphery
GO:2000114 regulation of establishment of cell polarity
Molecular Function GO:0002020 protease binding
GO:0035254 glutamate receptor binding
GO:0035255 ionotropic glutamate receptor binding
GO:0046982 protein heterodimerization activity
Cellular Component GO:0001669 acrosomal vesicle
GO:0001931 uropod
GO:0002080 acrosomal membrane
GO:0005901 caveola
GO:0005913 cell-cell adherens junction
GO:0005924 cell-substrate adherens junction
GO:0005925 focal adhesion
GO:0005938 cell cortex
GO:0015629 actin cytoskeleton
GO:0016323 basolateral plasma membrane
GO:0016600 flotillin complex
GO:0030027 lamellipodium
GO:0030055 cell-substrate junction
GO:0030139 endocytic vesicle
GO:0030141 secretory granule
GO:0030659 cytoplasmic vesicle membrane
GO:0030667 secretory granule membrane
GO:0030863 cortical cytoskeleton
GO:0030864 cortical actin cytoskeleton
GO:0031252 cell leading edge
GO:0031254 cell trailing edge
GO:0044291 cell-cell contact zone
GO:0044448 cell cortex part
GO:0044853 plasma membrane raft
GO:0045121 membrane raft
GO:0097223 sperm part
GO:0098589 membrane region
GO:0098857 membrane microdomain
GO:0099503 secretory vesicle
GO:0099568 cytoplasmic region
> KEGG and Reactome Pathway
 
KEGG hsa04910 Insulin signaling pathway
Reactome R-HSA-112316: Neuronal System
R-HSA-6794362: Protein-protein interactions at synapses
R-HSA-8849932: SALM protein interactions at the synapses
Summary
SymbolFLOT2
Nameflotillin 2
Aliases ECS-1; ECS1; Flotillin 2 (epidermal surface antigen 1); membrane component, chromosome 17, surface marker 1 ......
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between FLOT2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolFLOT2
Nameflotillin 2
Aliases ECS-1; ECS1; Flotillin 2 (epidermal surface antigen 1); membrane component, chromosome 17, surface marker 1 ......
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of FLOT2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen Total # shRNA with >= 4-fold: 1 Resistant to T-cell proliferation
24476824shRNAmelanomaB16Secondary screen Total # shRNA with >= 4-fold: 1 Resistant to T-cell proliferation
Summary
SymbolFLOT2
Nameflotillin 2
Aliases ECS-1; ECS1; Flotillin 2 (epidermal surface antigen 1); membrane component, chromosome 17, surface marker 1 ......
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of FLOT2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.7570.00811
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.6610.798
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.8340.643
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2040.527
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.4820.846
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.1470.963
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0370.92
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0920.956
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1380.943
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.4240.839
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.2510.936
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0430.582
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of FLOT2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolFLOT2
Nameflotillin 2
Aliases ECS-1; ECS1; Flotillin 2 (epidermal surface antigen 1); membrane component, chromosome 17, surface marker 1 ......
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FLOT2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolFLOT2
Nameflotillin 2
Aliases ECS-1; ECS1; Flotillin 2 (epidermal surface antigen 1); membrane component, chromosome 17, surface marker 1 ......
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FLOT2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FLOT2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolFLOT2
Nameflotillin 2
Aliases ECS-1; ECS1; Flotillin 2 (epidermal surface antigen 1); membrane component, chromosome 17, surface marker 1 ......
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FLOT2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolFLOT2
Nameflotillin 2
Aliases ECS-1; ECS1; Flotillin 2 (epidermal surface antigen 1); membrane component, chromosome 17, surface marker 1 ......
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of FLOT2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolFLOT2
Nameflotillin 2
Aliases ECS-1; ECS1; Flotillin 2 (epidermal surface antigen 1); membrane component, chromosome 17, surface marker 1 ......
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between FLOT2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolFLOT2
Nameflotillin 2
Aliases ECS-1; ECS1; Flotillin 2 (epidermal surface antigen 1); membrane component, chromosome 17, surface marker 1 ......
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting FLOT2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.